pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$MRNAModerna, Inc.

$MRNA150.79+13.10%
Cambridge, MA, USupdated 3h ago

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
18
marketed
5
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(18)

view full pipeline →
pipeline depth18 products
Phase 1: 5Phase 2: 5Phase 3: 1Marketed: 5pre_registration: 2
5Phase 15Phase 21Phase 35Marketed2pre_registration
Marketed
Coronavirus Disease 2019 (COVID-19) KP.2 vaccine
Coronavirus Disease 2019 (COVID-19)
Marketed
Coronavirus Disease 2019 (SARS-CoV-2) vaccine 2
Coronavirus Disease 2019 (COVID-19)
Marketed
davesomeran + elasomeran
Coronavirus Disease 2019 (COVID-19)
Marketed
elasomeran
Coronavirus Disease 2019 (COVID-19)
Marketed
mNEXSPIKE
Coronavirus Disease 2019 (COVID-19)
Phase 3
mRNA-1403
Norovirus Infections
Phase 2
intismeran autogene
Metastatic Melanoma
Phase 2
mRNA-3705
Methylmalonic Acidemia
Phase 2
mRNA-3927
Propionic Acidemia
Phase 2
mRNA-4359
Solid Tumor
Phase 2
respiratory syncytial virus vaccine
Respiratory Syncytial Virus (RSV) Infections
Fusion glycoprotein F0
Phase 1
mRNA-1215
Nipah Virus (NiV) Infections

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Jul 31, 2026
earnings
$MRNA150.79+13.10%
21d ago
Moderna, Inc. earnings
Moderna, Inc.
→
view all catalysts →

Wall Street consensus

source: yahoo finance · 20 analysts
mean target
$46.10
vs $49.56 now
implied upside
-7.0%
range: $21.00 – $135.00
consensus rating
Hold
2.96 / 5.0
rating distribution · 23 analysts
1
2
17
1
2
strong buystrong sell

recent actions (2)

  • Apr 2, 26REITBarclays→ Equal-Weight
  • Feb 23, 26REITPiper Sandler→ Overweight

Insider activity

source: SEC Form 4

open-market buys + sells

  • Mar 2, 26SELLKlinger Shannon Thyme· Chief Legal Officer13,885 sh @ $52.29−$726K↗
  • Feb 23, 26SELLHoge Stephen· President160,009 sh @ $48.84−$7.81M↗
routine RSU / option mechanics (6)
  • Apr 2, 26tax coverMock James M · Chief Financial Officer703 sh
  • Apr 2, 26option exerciseMock James M · Chief Financial Officer1,453 sh
  • Apr 2, 26option exerciseMock James M · Chief Financial Officer1,453 sh
  • Mar 5, 26tax coverMock James M · Chief Financial Officer5,704 sh
  • Mar 5, 26tax coverKlinger Shannon Thyme · Chief Legal Officer5,704 sh
  • Mar 5, 26option exerciseMock James M · Chief Financial Officer11,797 sh
🐶 Hiring Signal
184 open roles at Moderna, Inc. →

Where Moderna, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaInfectious Disease & Vaccines 13Oncology 11Immunology & Inflammation 3CNS / Neuroscience 1
departmentIT & Engineering 38R&D / Discovery 24Manufacturing / CMC 19Regulatory 13Quality 12Market Access 6

News

  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    stat · 3h ago
  • STAT+: Pharmalittle: We’re reading about a big Roche investment in the U.S., estrogen patch shortages, and more
    Roche's Genentech will invest $750 million to double the size of its existing production facility in Oregon
    stat · 3h ago
  • STAT+: FDA approves Ultragenyx gene therapy
    Regeneron wins ultra-rare disease drug approval, a validating win for mRNA research, and more biotech news from The Readout
    stat · 1d ago
  • Contrasting legal decisions on gender-affirming care
    Heidi Overton's rise under Trump, inside a 5-year-old brain organoid, and other health news from Morning Rounds
    stat · 1d ago
  • STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
    A Regeneron drug for an ultra-rare disease that causes bone to grow where it shouldn't won U.S. regulatory approval, capping a three-decade effort
    stat · 1d ago
  • Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
    Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.
    biospace · 1d ago
  • STAT+: One of the most consequential years for cancer treatment, ever
    Between success with a pancreatic cancer drug and now success with an mRNA neoantigen vaccine, it has been a banner year for developing cancer therapies.
    stat · 1d ago
  • Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
    As the dust settles on phase 3 data that added $45 billion to Moderna’s market cap, analysts have begun to ask a question that could define cancer care in the coming years: Can use of the vaccine b…
    fiercebiotech · 1d ago
  • Opinion: Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
    “Regulatory flexibility can be exercised in rare disease without sacrificing rigor,” writes Mindy Leffler, whose son has Duchenne muscular dystrophy.
    stat · 1d ago
  • 7 biopharma M&A deals where layoffs followed
    Workforce cuts this year at seven companies involved in recent mergers and acquisitions will cost over 1,300 employees their jobs. Affected businesses include Arcellx and Tourmaline Bio, acquired b…
    biospace · 1d ago
view all news mentions →
identifiers
ticker
$MRNA
SEC CIK
0001682852
country
US
source
sec_tickers
top tags
Infectious Disease13Oncology3Colorectal Cancer1NSCLC1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 21m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?